Citi raises Eli Lilly price target to $1,600 as weight-loss drug shares slide

Citi raised its 12-month price target on Eli Lilly to $1,600 from $1,500 on September 14, 2026, keeping a Buy rating even as the drugmaker's shares slid ^[1]. Analyst Geoff Meacham described the company's incretin franchise — the business built around tirzepatide, sold as Mounjaro and Zepbound — as a structural, multi-year story rather than a short-term trade ^[1].

Lilly closed at $1,114.90 on September 13, 2026, down 8.44% over the prior month from $1,218.49, while the S&P 500 fell 1.06% over the same period ^[1]. The average Wall Street 12-month target is $1,318.66, about 18% above that close. Citi's $1,600 is the Street high and implies roughly 44% upside ^[1]. Thirty firms cover Lilly, and the ratings split into 6 Strong Buy, 18 Buy, 4 Hold, 1 Sell and 1 Strong Sell ^[1].

Two things drove the pullback, according to the coverage. Realized U.S. prices dropped roughly 9% excluding rebate adjustments, feeding a narrative that the incretin market is entering a price-war phase, and Lilly recorded $2.78 billion in acquired in-process research and development charges tied to deals including Orna, Kelonia, Ajax and Centessa, which complicated reported earnings ^[1]. Operating results moved the other way: second-quarter revenue rose 48% year over year, and Lilly raised full-year 2026 revenue guidance to $85 billion to $87 billion ^[1]. A separate analysis puts year-over-year revenue growth at 49.58%, a slightly different figure for the same quarter ^[2].

Citi's bull case rests on three pillars ^[1]. Mounjaro and Zepbound hold roughly 6 of every 10 U.S. obesity prescriptions and about 7 of 10 injectable ones. Foundayo, the once-daily oral GLP-1 (orforglipron), grew from 8,000 to 36,000 prescribers in a single quarter, with a global rollout set for 2027. And retatrutide, a triple agonist, is slated for a regulatory filing in the first quarter of 2027. The bear case is that the 9% U.S. price decline excluding rebate adjustments marks the start of a margin unwind for Zepbound ^[1].

Retatrutide's 12 mg dose produced an average weight loss of 70.3 pounds, or 28.3%, over 80 weeks in people with obesity in its Phase 3 program, and Clarivate projects $30 billion in revenue by 2031 with a 2028 launch window ^[2]. Foundayo generated $98 million in its first reported quarter, with Clarivate projecting $16 billion in sales by 2031 ^[2]. The reports differ on combined Mounjaro and Zepbound quarterly revenue: roughly $14.9 billion in one ^[1] and $15.7 billion in the other ^[2].

The balance sheet carries its own risk. Lilly reported total debt of $108.4 billion, net debt of $46 billion and capital spending of $9.9 billion over the trailing twelve months ^[2]. It trades at 62.8 times forward earnings, against Novo Nordisk's 10.8 times trailing earnings ^[2]. Novo shares traded at $43.07, down 5.96% over the month, with a consensus target of $47.23 ^[1].

Why it matters for patients

The 9% decline in realized U.S. prices excluding rebate adjustments is the figure both the bull and bear cases hinge on ^[1]. It describes what Lilly collects per prescription in the United States, not what any one patient pays: list prices, insurance coverage and rebate arrangements all sit between the two, and no source here says how or whether that decline reaches out-of-pocket costs at the pharmacy counter.

Prescription share is the other number with practical weight. Tirzepatide's roughly 60% share of U.S. obesity prescriptions and 70% of injectable ones ^[1] reflect how widely these drugs are already prescribed, and analysts are openly debating whether oral options like Foundayo pull users away from injectables faster than Lilly can convert them ^[1].

Retatrutide is not available. Its Phase 3 results — 28.3% average weight loss over 80 weeks at the 12 mg dose ^[2] — come from a trial, and a filing is planned, not submitted ^[1][2].

What happens next

• Retatrutide: a Biologics License Application is planned for the first quarter of 2027, with a 2028 launch window ^[1][2].
• Foundayo: an international rollout is set for 2027 ^[1].
• Tirzepatide: a label expansion into cardiovascular risk was approved August 28, 2026 ^[1].

Whether the U.S. price decline continues, and how it affects net prices for patients, has not been disclosed.